Merus N.V. (MRUS) Announces Receipt of Undisclosed Milestone from Ono Pharma

October 19, 2016 7:02 AM EDT
Get Alerts MRUS Hot Sheet
Trade MRUS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Merus N.V. (Nasdaq: MRUS) announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’), under the ongoing collaboration between the two companies. The milestone was triggered as a result of pre-clinical confirmatory studies using the selected lead bispecific antibody candidate that Ono intends to advance into clinical testing. Ono and Merus have also extended their collaboration by signing an additional agreement for CMC activities to be carried out by Merus.

“Our research partnership with Ono continues to move ahead of schedule and yield promising results demonstrating the broad applicability of our Biclonics® platform,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “This proprietary technology, which generates full-length human IgG antibodies, allows for the rapid identification of bispecifics with functionality that is superior to conventional monoclonal antibodies. We are delighted that our work with Ono has resulted in the generation of a therapeutic candidate for autoimmune and related diseases that warrants further evaluation in a clinical setting, and we look forward to developing additional innovative therapeutics with this world-class partner.”

In April 2014, Merus and Ono executed a research and license agreement to jointly develop bispecific antibody therapies in autoimmune diseases. In April 2015, Merus received a milestone payment for achieving preclinical proof-of-concept with a lead bispecific antibody.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment